G. Hawks

A phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer (RCC).

W. Linehan, R. Srinivasan, C. Vocke, 2012 .

Malignant ascites as a manifestation of advanced papillary renal cell cancer (pRCC).

W. Linehan, R. Srinivasan, James Peterson, 2015 .

Development and validation of a multivariate predictor of mortality in very low birth weight.

K. Aleš, M. Druzin, W. Frayer, 1988, Journal of clinical epidemiology.

A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo‐immunized patients

S. Adams, W. Flegel, R. Childs, 2020, British journal of haematology.

5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib

P. Choyke, W. Linehan, R. Srinivasan, 2014 .